Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Sirolimus

6c74ec0b-68e4-5e77-9656-7b458c3ddc32 · FDA Approved · targets FKBP12, MTOR_FRAP1

Sirolimus

MeasuredReference

Sirolimus has no high-confidence primary targets in the catalog. Strongest hallmark effect: evading apoptosis.

Primary targets

No high-confidence primary targets.

Top hallmarks

  • evading apoptosis647
  • tumor promoting inflammation627
  • proliferation583

Top pathways disrupted

No pathway data.

Resistance landscape — Sirolimus

MeasuredReference

No variant annotations found on Sirolimus's top targets.

No variant annotations on Sirolimus's top targets.
Open in new tab